GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qyuns Therapeutics Co Ltd (HKSE:02509) » Definitions » EBITDA

Qyuns Therapeutics Co (HKSE:02509) EBITDA : HK$-258.47 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Qyuns Therapeutics Co EBITDA?

Qyuns Therapeutics Co's EBITDA for the three months ended in Jun. 2024 was HK$0.00 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-258.47 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Qyuns Therapeutics Co's EBITDA per Share for the three months ended in Jun. 2024 was HK$0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.16.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


Qyuns Therapeutics Co EBITDA Historical Data

The historical data trend for Qyuns Therapeutics Co's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qyuns Therapeutics Co EBITDA Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23
EBITDA
-469.04 -293.86 -516.51

Qyuns Therapeutics Co Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24
EBITDA Get a 7-Day Free Trial -104.69 - -123.93 -134.54 -

Competitive Comparison of Qyuns Therapeutics Co's EBITDA

For the Biotechnology subindustry, Qyuns Therapeutics Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qyuns Therapeutics Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Qyuns Therapeutics Co's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Qyuns Therapeutics Co's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Qyuns Therapeutics Co's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, Qyuns Therapeutics Co's EBITDA was HK$-516.51 Mil.

Qyuns Therapeutics Co's EBITDA for the quarter that ended in Jun. 2024 is calculated as

EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-258.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Qyuns Therapeutics Co  (HKSE:02509) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Qyuns Therapeutics Co EBITDA Related Terms

Thank you for viewing the detailed overview of Qyuns Therapeutics Co's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Qyuns Therapeutics Co Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline.
Executives
Zhu Jing
Taizhou Xinfu Tongxin Enterprise Management Partnership (limited Partnership)
Tai Zhou Yi Yao Gao Xin Ji Shu Chan Ye Tou Zi Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Qu Hua Yin Jin Rong Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Qing Dao Xin Chen Ke Chuang Shi Ye You Xian Gong Si
Zi Jin Xin Tuo You Xian Ze Ren Gong Si
Tai Zhou Hua Cheng Yi Xue Tou Zi Ji Tuan You Xian Gong Si
Nan Jing Zi Jin Tou Zi Ji Tuan You Xian Ze Ren Gong Si
Nan Jing Shi Guo You Zi Chan Tou Zi Guan Li Kong Gu Ji Tuan You Xian Ze Ren Gong Si
Bei Jing Hong Tai Tong Chuang Tou Zi Guan Li You Xian Gong Si
Sheng Xi Tai
Tai Zhou Yi Yao Cheng Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Hu Kaijun 2201 Interest of corporation controlled by you
Yu Guo'an
Hangzhou Quanyi Investment Management Partnership (general Partnership)

Qyuns Therapeutics Co Headlines

No Headlines